Company profile
Entrada Therapeutics, Inc.
NASDAQ: TRDA · Healthcare · Biotechnology
#524 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
46DFH 44DQ 48GM —SS 52
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$5.7M
Rev growth YoY (TTM)
-96.7%
Net income (FY)
-$143.8M
Employees
152
as of 2026-08-13
Market cap
$297.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$25.4M$25.4M2025
Net income-$143.8M-$143.8M2025
Operating income-$157.9M-$157.9M2025
Total assets$377.4M$377.4M2025
Liabilities$71.2M$71.2M2025
Equity$306.1M$306.1M2025
Revenue trend
FY2023 – FY2025 · USD
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License100%
By geography
Not disclosed.
The read
What is Entrada Therapeutics, Inc.’s revenue?
Entrada Therapeutics, Inc. booked $25.4M in FY2025 revenue, contracting 88% year over year — slower than 90% of Healthcare companies we track, at a -565.5% net margin.
Peers · Healthcare
RBC Life Sciences, Inc.——Gelesis Holdings, Inc.——Avant Brands Inc.59CMetagenomi, Inc. Common Stock40DIonic Brands Corp.——Halo Collective Inc.——Neighbors
Suffolk →Key facts
CEODipal Doshi
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
ExchangeNASDAQ: TRDA
Employees152
IPO date2021-10-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.